Clinical Trials in Maryland

Showing 6141-6160 of 17,687 trials

Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis

NCT05953545

Background: Chronic hepatitis D is a serious liver disease caused by a virus. Currently, no medications are approved to treat chronic hepatitis D. Objective: To test a combination of 3 drugs in people with chronic hepatitis D. Eligibility: People 18 years or older with chronic hepatitis D. Design: Participants will be in the study about 2 years. They will have 3 inpatient stays of 3 to 5 days. Participants will be screened. They will have a physical exam with blood tests. They will have a test of their heart function and an ultrasound: a wand that uses sound waves to create images of the liver will be rubbed over the skin on their torso. Participants will stay in the clinic for a 3-day baseline visit. They will have imaging scans, an eye exam, and a visit with a reproductive specialist. They will have a liver biopsy: about 1 inch of liver tissue will be removed, either with a tube inserted through a vein in the neck, or with a needle inserted through the participant s side. Participants will take the study drugs for 48 weeks. Two of them are tablets taken twice a day at home; 1 is a shot administered once a week. Participants will begin taking the drugs during a 5-day stay in the clinic. Then they will have 15 outpatient visits while taking the drugs and 7 more after they finish. The last 3-day clinic stay will be 6 months after participants finish taking the drugs. The liver biopsy, imaging scans, and other tests will be repeated.

Chronic Hepatitis Delta

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Started May 2024

Bethesda, Maryland, United States

COMPLETEDPhase 319 miles

Safety and Efficacy of Emixustat in Stargardt Disease

NCT03772665

The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease. Funding Source -- FDA OOPD

Stargardt Disease

Kubota Vision Inc.194 participantsStarted Jan 2019

Beverly Hills, California, United States • San Francisco, California, United States • Atlanta, Georgia, United States +26 more locations

Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis

Safety and Efficacy of Emixustat in Stargardt Disease

Find Trials by Condition in Maryland

Surgical Site Infection and Antibiotic Use Study

A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

Predictors of Severe COVID-19 Outcomes

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

IN.PACT™ AV Access IDE Study

A Study of B + L Ophthalmic Viscosurgical Device (OVD) CVisc50

A Study to Evaluate Ketamine for the Treatment of Rett Syndrome

Use of Oxandrolone to Promote Growth in Infants With HLHS

Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain

Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions

Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia

Retrospective Study of Glucose Monitoring for Glycemic Control in Patients With GSDIa

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)